U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H29N3O3
Molecular Weight 431.5268
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIRBANIBULIN

SMILES

O=C(CC1=NC=C(C=C1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4

InChI

InChIKey=HUNGUWOZPQBXGX-UHFFFAOYSA-N
InChI=1S/C26H29N3O3/c30-26(28-19-21-4-2-1-3-5-21)18-24-9-6-23(20-27-24)22-7-10-25(11-8-22)32-17-14-29-12-15-31-16-13-29/h1-11,20H,12-19H2,(H,28,30)

HIDE SMILES / InChI

Description

KX-01 is a dual inhibitor of Src kinase and tubulin polymerization. KX01 promotes the induction of p53, G2/M arrest of proliferating cell populations and subsequent apoptosis via the stimulation of Caspase-3 and PARP cleavage. The drug was developed by Kinex Pharmaceuticals and reached phase II of clinical trials for the treatment of Castration-Resistant Prostate Cancer and Actinic Keratosis. KX-01 demonstrated good in vitro pofile against different cancer cell lines with IC50 in nanomolar range.

Approval Year

PubMed

PubMed

TitleDatePubMed
Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro.
2009 Jul
Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors.
2011 Apr 15
Thiazolyl N-benzyl-substituted acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities.
2011 Oct
KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer.
2012 Apr
A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.
2013 Aug
Patents

Sample Use Guides

In Vivo Use Guide
Patients recieve 40 mg of oral KX-01 twice-daily. Ointment form should be applied once daily.
Route of Administration: Oral; Topical
In Vitro Use Guide
PC3-LN4 human prostate cancer cells were treated with 10(-4)-10(4) nM of KX-01 for 72 hours and GI50 value was determined to be 40 nM.
Name Type Language
TIRBANIBULIN
INN  
Official Name English
KX-2-391
Code English
2-PYRIDINEACETAMIDE, 5-(4-(2-(4-MORPHOLINYL)ETHOXY)PHENYL)-N-(PHENYLMETHYL)-
Systematic Name English
N-BENZYL-2-(5-(4-(2-MORPHOLIN-4-YLETHOXY)PHENYL)PYRIDIN-2-YL)ACETAMIDE
Systematic Name English
TIRBANIBULIN [INN]
Common Name English
KX-01
Common Name English
KX-2391
Code English
KX2-391
Code English
Code System Code Type Description
ChEMBL
CHEMBL571546
Created by admin on Tue Oct 22 08:19:54 UTC 2019 , Edited by admin on Tue Oct 22 08:19:54 UTC 2019
PRIMARY
EPA CompTox
897016-82-9
Created by admin on Tue Oct 22 08:19:54 UTC 2019 , Edited by admin on Tue Oct 22 08:19:54 UTC 2019
PRIMARY
PUBCHEM
23635314
Created by admin on Tue Oct 22 08:19:54 UTC 2019 , Edited by admin on Tue Oct 22 08:19:54 UTC 2019
PRIMARY
CAS
897016-82-9
Created by admin on Tue Oct 22 08:19:54 UTC 2019 , Edited by admin on Tue Oct 22 08:19:54 UTC 2019
PRIMARY
INN
10864
Created by admin on Tue Oct 22 08:19:54 UTC 2019 , Edited by admin on Tue Oct 22 08:19:54 UTC 2019
PRIMARY